Chromosomal region maintenance 1 (CRM1) can be a valid target in ovarian cancer and S109, a CRM1 inhibitor could be a potent anti-tumor agent for ovarian cancer treatment.
- Many CRM1 inhibitors have been described previously but are irreversible but S109 is a reversible CRM1 inhibitor in ovarian cancer cells.
- Cytoplasmic Foxo1 has been shown to be particularly high expression both in paclitaxel-resistant ovarian cancer cell lines and clinical samples and hence could be a molecular target for the treatment of sensitive or drug-resistant ovarian cancers.
- A therapeutic strategy simultaneously targeting multiple oncogenic pathways or targets might be a rational and effective strategy in ovarian cancer.
CitationLiu X, Chong Y, Liu H, Han Y, Niu M. Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer. J Ovarian Res. 2015 Jun 10; 8(1):35.